Cantor Fitzgerald analyst, Louise Chen, reiterated her Overweight rating on shares of Heron Therapeutics (NASDAQ: HRTX) and defended shares after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE